Page 265 - Eshre Final Programme 2015

P-624 Maternal dietary exposure to bisphenol-A (BPA) increases embryo size and alters key epigenetic regulators in the blastocyst
A.E. Batcheller1, A. Cheong2, G.L. Christiansen1, M.A. Thomas1, S.M. Ho2, Y.K. Leung2
1University of Cincinnati, Obstetrics and Gynecology, West Chester OH, U.S.A. 2University of Cincinnati, Environmental Health, Cincinnati OH, U.S.A.
P-625 A combined Day5/Day 6 trofectoderm biopsy strategy followed by frozen embryo transfers can maximize the embryo utilization and clinical outcome in comprehensive chromosomal screening (CCS) cycles.
N. Findikli1, B. Capar2, B. Musul2, M. Gultomruk2, T. Aksoy1, E. Yagmur3, M. Bahceci3
1Bahceci Fulya IVF Centre, Embryology Laboratory, Istanbul, Turkey 2Bahceci Fulya IVF Centre, R&D Laboratory, Istanbul, Turkey 3Bahceci Fulya IVF Centre, Infertility Clinic, Istanbul, Turkey
P-626 Comparison of clinic outcomes of preimplantation genetic screening (PGS) in elder patients, repeated miscarriage or those once with fetus of abnormal CGH
K.L. Luo1, F. Gong1, Y.Q. Tan1, Y.F. Gu1, G. Lin1, G.X. Lu1, F. Gong1, K. Tan1
1Citic-Xiangya Reproductive& Genetic Hospital, IVF centre, Changsha, China
P-627 Mosaicism and DNA methylation at imprinted genes varies with severity of oligozoospermia in infertile men
R. Ng1, K. Louie1, K. Poon1, V. Chow1, S. Ma1
1University of British Columbia, Obstetrics and Gynaecology, Vancouver BC, Canada
P-628 Carrier Screening of 58,000 Patients in the IVF Setting Utilizing Next Generation DNA sequencing Detects Common, Rare and Otherwise Undetectable Mutations in Prevalent, Society- Recommended Diseases
N. Faukner1, T. Mullen1, V. Greger1, R. Rochelle2, A. Frieden3, S. Hallam1
1Good Start Genetics Inc., Clinical Laboratory, Cambridge MA, U.S.A. 2Good Start Genetics Inc., Marketing, Cambridge MA, U.S.A.
3Good Start Genetics Inc., Bioinformatics, Cambridge MA, U.S.A.
P-629 Significant skews in methylation fractions in previously described genotypes and sub-genotypes of the FMR1 gene
D. Barad1, A. Weghofer2, G.J. Latham3, S. Filipovic-Sadic3, V.A. Kushnir1, N. Gleicher1
1Center for Human Reproduction, N/A, New York NY, U.S.A. 2Medical University Vienna, Obstetrics & Gynecology, Vienna, Austria 3Asuragen Inc, N/A, Austin TX, U.S.A.
FINAL PROGRAMME I LISBON, PORTUGAL – 14 TO 17 JUNE 2015 265
POSTERS